Transgenomic: Pharmaceutical And Biotechnology Companies
The following excerpt is from the company's SEC filing.
(such as: Amgen, Inc., Novartis AG, Clovis Oncology, Inc., AstraZeneca plc, GlaxoSmithKline plc and Bristol-Myers Squibb Company). For companies developing new cancer drugs, MX-ICP has the potential to reduce the risk of clinical trials, as well as support the development of companion diagnostics to match drugs with patients.
Clinical Laboratories
(such as: Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated and the many CLIA-certified laboratories throughout the United States). MX-ICP would allow clinical laboratory firms to effectively compete with more specialized provider s and to become full service providers as personalized, precision medicine becomes more widely adopted.
The markets in which we compete require a wide variety of technologies, products and capabilities. The combination of technological complexity and rapid change within our markets makes it difficult for a single company to develop all of the solutions that it desires to offer as part of its family of products and services. We work to broaden the range of products and services we deliver to customers in target markets through acquisitions, investments and alliances. We employ the following strategies to address the need for new or enhanced products and services:
Developing new technologies and products internally;
Acquiring all or parts of other companies;
Entering into joint-development efforts with other companies; and
Reselling other companies’ products.
Our strategy is to leverage the discoveries in our Research and Development (R&D) and Biomarker Identification laboratories to create “kits” or assays to distribute through our Genetic Assays and Platforms segment, as well as tests to conduct in our Patient Testing laboratories.
We will continue to develop new applications for, and enhancements of, MX-ICP and capitalize on our expertise and intell Less
